Nicotine By-product Reduces Alzheimer's Telltale Plaques
By Sarah Graham
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
The downsides of smoking are plentiful, ranging from stained fingers and teeth to an increased risk of lung cancer. But one potential upside was discovered recently when research suggested that cigarette smoking may delay the onset of Alzheimer's disease. Findings published online this week by the Proceedings of the National Academy of Sciences indicate that nornicotine, a by-product of nicotine, could be responsible for this protective effect.
Kim Janda and Tobin Dickerson of the Scripps Research Institute tested the effect of nornicotine on amyloid beta proteins, which aggregate into the plaques that are a hallmark of Alzheimer's disease. Specifically, the researchers found that a reaction known as glycation, which occurs between the molecule and sugars, alters amyloid proteins so that fewer plaques can form. The authors note that together with nicotine, nornicotine is an intriguing and potentially valuable treatment for Alzheimer's disease. Both compounds are toxic, however, so the scientists suggest investigating new therapies that can mimic their beneficial results without harmful side effects.
Subscribe to Support Independent Journalism
Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.
When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.
Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber
